A portrait of research participant Amber wearing a gray-blue sweater and standing beside a brick wall
Participant Spotlight

Immunotherapy proven to slow T1D progression in people newly diagnosed now being tested for prevention

Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.

Read more
Subscribe to ATG